Stockscreener 앱 받기
0.2232
5.33%
0.0113
시장 영업 전:
.22
-0.0032
-1.43%
Theriva Biologics Inc 주식(TOVX)의 최신 뉴스
Portfolio Recap: Does Theriva Biologics Inc have strong EBITDA margins2026 Movers & Weekly Top Gainers Trade List - baoquankhu1.vn
Maxim Group Maintains Theriva Biologics(TOVX.US) With Hold Rating - Moomoo
Maxim Group Maintains Theriva Biologics(TOVX.US) With Hold Rating, Announces Target Price $0.22 - Moomoo
Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA - TipRanks
Theriva Biologics Receives FDA Agreement to Advance VCN-01 to Phase 3 Trial for Metastatic Pancreatic Cancer 1 - Minichart
Theriva Biologics Announces Positive End-Of-Phase 2 Meeting With U.S. FDA Regarding The Design Of A Phase 3 Trial Of VCN-01 In Metastatic Pancreatic Ductal Adenocarcinoma - marketscreener.com
Theriva™ Biologics reports full-year 2025 operational highlights and financial results - MSN
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Stocktwits
Theriva Biologics (TOVX) Advances Phase 3 Clinical Trial Plans f - GuruFocus
Theriva Biologics Advances VCN-01 Into Pivotal Phase 3 - TipRanks
Theriva gets FDA alignment on phase 3 trial design for VCN-01 - Investing.com Canada
Theriva Biologics aligns with FDA on Phase 3 VCN-01 design for metastatic PDAC - TradingView
Theriva Biologics (NYSE: TOVX) gains FDA alignment on pivotal VCN-01 Phase 3 in metastatic PDAC - Stock Titan
Theriva pushes pancreatic cancer drug VCN-01 toward Phase 3 - Stock Titan
If You Invested $1,000 in THERIVA BIOLOGICS INC (TOVX) - Stock Titan
Theriva Biologics (TOVX) Registration Filing Summary - Quartr
Chart Watch: Is Theriva Biologics Inc showing insider buying2026 Technicals & Target Return Focused Stock Picks - baoquankhu1.vn
TOVX Stock Price, Quote & Chart | THERIVA BIOLOGICS INC (NYSEARCA:TOVX) - ChartMill
Aug Swings: Will Theriva Biologics Inc outperform its industry peers2026 Key Lessons & Risk Managed Investment Signals - baoquankhu1.vn
Theriva Biologics (NYSE: TOVX) puts 16.2M warrant share issuance to vote - Stock Titan
Theriva Biologics, Inc. (TOVX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Theriva Biologics Reports Full-Year 2025 Operational Highlights and Financial Results - Bitget
TOVX Reports Strong Cash Position and Funding Plans for Clinical Trials - GuruFocus
Theriva 10-K: Net loss $23.74M, EPS $(2.08); Operating loss $24.05M - TradingView
Theriva Biologics reports $13.1M year-end cash, $25.2M net loss for 2025 - TradingView
Form 10-K Theriva Biologics, Inc. For: Dec 31 - StreetInsider
Theriva Biologics (NYSE: TOVX) details 2025 loss and cash runway into 2027 - Stock Titan
Cancer drug developer Theriva inks SYN-020 deal up to $38M - Stock Titan
TOVX Advances Oncology Pipeline with Strategic Licensing and Cli - GuruFocus
Theriva Biologics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Mood: Can Theriva Biologics Inc maintain sales growthStock Surge & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Aug Shorts: Can Theriva Biologics Inc maintain sales growthAnalyst Upgrade & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 - Stocktwits
TOVX Should I Buy - Intellectia AI
TOVX SEC FilingsTHERIVA BIOLOGICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Stocktwits
TOVX Technical Analysis & ETF Price Forecast - Intellectia AI
Is Theriva Biologics Inc. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - mfd.ru
TOVX Theriva Biologics AMEX pre-market +12% Feb 20 2026: Most active - Meyka
$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum - GlobeNewswire Inc.
Aug Update: What are Theriva Biologics Incs technical support levelsJuly 2025 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Theriva Biologics licenses Syn-020 to Rasayana Therapeutics for multiple indications - marketscreener.com
Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications - TradingView
Theriva Biologics (TOVX) Licenses SYN-020 to Rasayana Therapeuti - GuruFocus
Theriva Licenses SYN-020, Refocuses on Cancer Pipeline - TipRanks
Theriva Biologics Inc (referred to as Theriva Biologics) has successfully received a $300,000 upfront payment at the time of signing the agreement. - Bitget
Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Bitget
How Theriva Biologics Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Daily Price Action Insights - mfd.ru
Published on: 2026-02-14 06:14:36 - mfd.ru
Theriva Biologics Faces Delay in Warrant Approval Meeting - The Globe and Mail
How Theriva Biologics Inc. stock correlates with oil marketsM&A Rumor & Comprehensive Market Scan Insights - mfd.ru
Will Theriva Biologics Inc. outperform its industry peersWeekly Stock Report & Low Drawdown Trading Strategies - mfd.ru
Theriva Biologics Reschedules Stockholder Meeting - TradingView
Theriva Biologics (NYSE: TOVX) to reschedule vote on 16.18M warrant shares - Stock Titan
Death Cross: Can Theriva Biologics Inc. grow without dilutionJuly 2025 Selloffs & Daily Entry Point Trade Alerts - mfd.ru
Published on: 2026-02-09 23:08:24 - mfd.ru
Analyst Downgrade: Why is Theriva Biologics Inc stock going downJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Bond Watch: Is Theriva Biologics Inc. subject to activist investor interest2025 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - baoquankhu1.vn
Theriva™ Biologics Announces Upcoming Presentation of Data - GlobeNewswire
Trial tests VCN-01 before eye removal in hard-to-treat retinoblastoma - Stock Titan
Street Watch: Is Theriva Biologics Inc showing insider buyingWeekly Market Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Is Theriva Biologics Inc backed by strong institutional buyingJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 4.9% – Time to Sell? - Defense World
Dow Update: Can Theriva Biologics Inc continue delivering strong returnsWeekly Trade Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
1.82%
자본화:
|
볼륨(24시간):